Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 84

1.

Eligibility for anti-fibrotic treatment in idiopathic pulmonary fibrosis depends on the predictive equation used for pulmonary function testing.

Burgess A, Goon K, Brannan JD, Attia J, Palazzi K, Oldmeadow C, Corte TJ, Glaspole I, Goh N, Keir G, Allan H, Chapman S, Cooper W, Ellis S, Hopkins P, Moodley Y, Reynolds P, Zappala C, Macansh S, Grainge C.

Respirology. 2019 Mar 28. doi: 10.1111/resp.13540. [Epub ahead of print]

PMID:
30924257
2.

DNA nanostructures coordinate gene silencing in mature plants.

Zhang H, Demirer GS, Zhang H, Ye T, Goh NS, Aditham AJ, Cunningham FJ, Fan C, Landry MP.

Proc Natl Acad Sci U S A. 2019 Apr 9;116(15):7543-7548. doi: 10.1073/pnas.1818290116. Epub 2019 Mar 25.

PMID:
30910954
3.

High aspect ratio nanomaterials enable delivery of functional genetic material without DNA integration in mature plants.

Demirer GS, Zhang H, Matos JL, Goh NS, Cunningham FJ, Sung Y, Chang R, Aditham AJ, Chio L, Cho MJ, Staskawicz B, Landry MP.

Nat Nanotechnol. 2019 Feb 25. doi: 10.1038/s41565-019-0382-5. [Epub ahead of print]

PMID:
30804481
4.

Therapeutic burden in interstitial lung disease: Lessons to learn.

Khor YH, Glaspole I, Goh NSL.

Respirology. 2019 Feb 20. doi: 10.1111/resp.13480. [Epub ahead of print]

PMID:
30790404
5.

Exertional Desaturation and Prescription of Ambulatory Oxygen Therapy in Interstitial Lung Disease.

Khor YH, Goh NS, Glaspole I, Holland AE, McDonald CF.

Respir Care. 2019 Mar;64(3):299-306. doi: 10.4187/respcare.06334. Epub 2018 Oct 30.

PMID:
30377245
6.

Ultralarge Modulation of Fluorescence by Neuromodulators in Carbon Nanotubes Functionalized with Self-Assembled Oligonucleotide Rings.

Beyene AG, Alizadehmojarad AA, Dorlhiac G, Goh N, Streets AM, Král P, Vuković L, Landry MP.

Nano Lett. 2018 Nov 14;18(11):6995-7003. doi: 10.1021/acs.nanolett.8b02937. Epub 2018 Oct 25.

PMID:
30350638
7.

Implications of the diagnostic criteria of idiopathic pulmonary fibrosis in clinical practice: Analysis from the Australian Idiopathic Pulmonary Fibrosis Registry.

Jo HE, Glaspole I, Goh N, Hopkins PMA, Moodley Y, Reynolds PN, Chapman S, Walters EH, Zappala C, Allan H, Macansh S, Grainge C, Keir GJ, Hayen A, Henderson D, Klebe S, Heinze SB, Miller A, Rouse HC, Duhig E, Cooper WA, Mahar AM, Ellis S, McCormack SR, Ng B, Godbolt DB, Corte TJ.

Respirology. 2019 Apr;24(4):361-368. doi: 10.1111/resp.13427. Epub 2018 Oct 17.

8.

Short- and Long-Term Reliability of the 6-Minute Walk Test in People With Idiopathic Pulmonary Fibrosis.

Holland AE, Hill CJ, Dowman L, Glaspole I, Goh N, Lee AL, McDonald CF.

Respir Care. 2018 Aug;63(8):994-1001. doi: 10.4187/respcare.05875. Epub 2018 Jun 26.

PMID:
29945909
9.

Nanoparticle-Mediated Delivery towards Advancing Plant Genetic Engineering.

Cunningham FJ, Goh NS, Demirer GS, Matos JL, Landry MP.

Trends Biotechnol. 2018 Sep;36(9):882-897. doi: 10.1016/j.tibtech.2018.03.009. Epub 2018 Apr 24. Review.

PMID:
29703583
10.

Catheter-related complications and survival among incident hemodialysis patients in Singapore.

Yap HY, Pang SC, Tan CS, Tan YL, Goh N, Achudan S, Lee KG, Tan RY, Choong LH, Chong TT.

J Vasc Access. 2018 Nov;19(6):602-608. doi: 10.1177/1129729818765055. Epub 2018 Mar 27.

PMID:
29582680
11.

Pulmonary hypertension in combined pulmonary fibrosis and emphysema: A tale of two cities.

Goh NSL.

Respirology. 2018 Jun;23(6):556-557. doi: 10.1111/resp.13289. Epub 2018 Mar 11. No abstract available.

12.

Diagnosis and management of idiopathic pulmonary fibrosis: Thoracic Society of Australia and New Zealand and Lung Foundation Australia position statements summary.

Jo HE, Prasad JD, Troy LK, Mahar A, Bleasel J, Ellis SJ, Chambers DC, Holland AE, Lake FR, Keir G, Goh NS, Wilsher M, de Boer S, Moodley Y, Grainge C, Whitford HM, Chapman SA, Reynolds PN, Beatson D, Jones LJ, Hopkins P, Allan HM, Glaspole I, Corte TJ.

Med J Aust. 2018 Feb 5;208(2):82-88.

PMID:
29385965
13.

Disease progression in idiopathic pulmonary fibrosis with mild physiological impairment: analysis from the Australian IPF registry.

Jo HE, Glaspole I, Moodley Y, Chapman S, Ellis S, Goh N, Hopkins P, Keir G, Mahar A, Cooper W, Reynolds P, Haydn Walters E, Zappala C, Grainge C, Allan H, Macansh S, Corte TJ.

BMC Pulm Med. 2018 Jan 25;18(1):19. doi: 10.1186/s12890-018-0575-y.

14.

Cyclophosphamide for connective tissue disease-associated interstitial lung disease.

Barnes H, Holland AE, Westall GP, Goh NS, Glaspole IN.

Cochrane Database Syst Rev. 2018 Jan 3;1:CD010908. doi: 10.1002/14651858.CD010908.pub2. Review.

PMID:
29297205
15.

Medical education system in Malaysia maintaining a gold standard - an extraordinary example from the Malaysian Society of Pharmacology and Physiology.

Roy B, Goh N, Malik RH.

Nepal J Epidemiol. 2017 Sep 30;7(3):697-698. doi: 10.3126/nje.v7i3.19008. eCollection 2017 Sep. No abstract available.

16.

Treatment of idiopathic pulmonary fibrosis in Australia and New Zealand: A position statement from the Thoracic Society of Australia and New Zealand and the Lung Foundation Australia.

Jo HE, Troy LK, Keir G, Chambers DC, Holland A, Goh N, Wilsher M, de Boer S, Moodley Y, Grainge C, Whitford H, Chapman S, Reynolds PN, Glaspole I, Beatson D, Jones L, Hopkins P, Corte TJ.

Respirology. 2017 Oct;22(7):1436-1458. doi: 10.1111/resp.13146. Epub 2017 Aug 27. Erratum in: Respirology. 2018 Jan;23 (1):116.

PMID:
28845557
17.

Determinants and outcomes of prolonged anxiety and depression in idiopathic pulmonary fibrosis.

Glaspole IN, Watson AL, Allan H, Chapman S, Cooper WA, Corte TJ, Ellis S, Grainge C, Goh N, Hopkins P, Keir G, Macansh S, Mahar A, Moodley Y, Reynolds PN, Ryerson CJ, Walters EH, Zappala CJ, Holland AE.

Eur Respir J. 2017 Aug 17;50(2). pii: 1700168. doi: 10.1183/13993003.00168-2017. Print 2017 Aug. No abstract available.

18.

Oxygen Therapy for Interstitial Lung Disease: Physicians' Perceptions and Experiences.

Khor YH, Goh NSL, McDonald CF, Holland AE.

Ann Am Thorac Soc. 2017 Dec;14(12):1772-1778. doi: 10.1513/AnnalsATS.201705-372OC.

PMID:
28796538
19.

Supplemental oxygen and dypsnoea in interstitial lung disease: absence of evidence is not evidence of absence.

Bell EC, Cox NS, Goh N, Glaspole I, Westall GP, Watson A, Holland AE.

Eur Respir Rev. 2017 Aug 9;26(145). pii: 170072. doi: 10.1183/16000617.0072-2017. Print 2017 Sep 30. No abstract available.

20.

Portable oxygen concentrators versus oxygen cylinder during walking in interstitial lung disease: A randomized crossover trial.

Khor YH, McDonald CF, Hazard A, Symons K, Westall G, Glaspole I, Goh NSL, Holland AE.

Respirology. 2017 Nov;22(8):1598-1603. doi: 10.1111/resp.13083. Epub 2017 May 23.

PMID:
28544460
21.

Short-Term Pulmonary Function Trends Are Predictive of Mortality in Interstitial Lung Disease Associated With Systemic Sclerosis.

Goh NS, Hoyles RK, Denton CP, Hansell DM, Renzoni EA, Maher TM, Nicholson AG, Wells AU.

Arthritis Rheumatol. 2017 Aug;69(8):1670-1678. doi: 10.1002/art.40130. Epub 2017 Jul 18.

22.

Oxygen Therapy for Interstitial Lung Disease. A Mismatch between Patient Expectations and Experiences.

Khor YH, Goh NSL, McDonald CF, Holland AE.

Ann Am Thorac Soc. 2017 Jun;14(6):888-895. doi: 10.1513/AnnalsATS.201611-934OC.

PMID:
28267349
23.

Baseline characteristics of idiopathic pulmonary fibrosis: analysis from the Australian Idiopathic Pulmonary Fibrosis Registry.

Jo HE, Glaspole I, Grainge C, Goh N, Hopkins PM, Moodley Y, Reynolds PN, Chapman S, Walters EH, Zappala C, Allan H, Keir GJ, Hayen A, Cooper WA, Mahar AM, Ellis S, Macansh S, Corte TJ.

Eur Respir J. 2017 Feb 23;49(2). pii: 1601592. doi: 10.1183/13993003.01592-2016. Print 2017 Feb. Erratum in: Eur Respir J. 2017 Mar 29;49(3):.

24.

Greater endurance capacity and improved dyspnoea with acute oxygen supplementation in idiopathic pulmonary fibrosis patients without resting hypoxaemia.

Dowman LM, McDonald CF, Bozinovski S, Vlahos R, Gillies R, Pouniotis D, Hill CJ, Goh NSL, Holland AE.

Respirology. 2017 Jul;22(5):957-964. doi: 10.1111/resp.13002. Epub 2017 Feb 22.

PMID:
28225205
25.

Oxygen therapy for interstitial lung disease: a systematic review.

Bell EC, Cox NS, Goh N, Glaspole I, Westall GP, Watson A, Holland AE.

Eur Respir Rev. 2017 Feb 21;26(143). pii: 160080. doi: 10.1183/16000617.0080-2016. Print 2017 Jan. Review.

26.

The evidence of benefits of exercise training in interstitial lung disease: a randomised controlled trial.

Dowman LM, McDonald CF, Hill CJ, Lee AL, Barker K, Boote C, Glaspole I, Goh NSL, Southcott AM, Burge AT, Gillies R, Martin A, Holland AE.

Thorax. 2017 Jul;72(7):610-619. doi: 10.1136/thoraxjnl-2016-208638. Epub 2017 Feb 17.

PMID:
28213592
27.

Health-related quality of life in idiopathic pulmonary fibrosis: Data from the Australian IPF Registry.

Glaspole IN, Chapman SA, Cooper WA, Ellis SJ, Goh NS, Hopkins PM, Macansh S, Mahar A, Moodley YP, Paul E, Reynolds PN, Walters EH, Zappala CJ, Corte TJ.

Respirology. 2017 Jul;22(5):950-956. doi: 10.1111/resp.12989. Epub 2017 Feb 6.

28.

Outcomes of arteriovenous fistula creation, effect of preoperative vein mapping and predictors of fistula success in incident haemodialysis patients: A single-centre experience.

Lee KG, Chong TT, Goh N, Achudan S, Tan YL, Tan RY, Choong HL, Tan CS.

Nephrology (Carlton). 2017 May;22(5):382-387. doi: 10.1111/nep.12788.

PMID:
27042772
29.

Apical lymph node dissection of the inferior mesenteric artery.

Goh N, Fong SS, How KY, Wong KY, Loong TH, Tay GT.

Colorectal Dis. 2016 Jun;18(6):O206-9. doi: 10.1111/codi.13299.

PMID:
26880360
30.

Combined Pulmonary Fibrosis and Emphysema in Scleroderma-Related Lung Disease Has a Major Confounding Effect on Lung Physiology and Screening for Pulmonary Hypertension.

Antoniou KM, Margaritopoulos GA, Goh NS, Karagiannis K, Desai SR, Nicholson AG, Siafakas NM, Coghlan JG, Denton CP, Hansell DM, Wells AU.

Arthritis Rheumatol. 2016 Apr;68(4):1004-12. doi: 10.1002/art.39528.

31.

Reliability of the hand held dynamometer in measuring muscle strength in people with interstitial lung disease.

Dowman L, McDonald CF, Hill CJ, Lee A, Barker K, Boote C, Glaspole I, Goh N, Southcott A, Burge A, Ndongo R, Martin A, Holland AE.

Physiotherapy. 2016 Sep;102(3):249-55. doi: 10.1016/j.physio.2015.10.002. Epub 2015 Oct 22.

PMID:
26596172
32.

Quantifying change in pulmonary function as a prognostic marker in systemic sclerosis-related interstitial lung disease.

Moore OA, Proudman SM, Goh N, Corte TJ, Rouse H, Hennessy O, Morrisroe K, Thakkar V, Sahhar J, Roddy J, Youssef P, Gabbay E, Nash P, Zochling J, Stevens W, Nikpour M.

Clin Exp Rheumatol. 2015 Jul-Aug;33(4 Suppl 91):S111-6. Epub 2015 Aug 5.

PMID:
26243401
33.

Agreement and mortality prediction in high-resolution CT of diffuse fibrotic lung disease.

Siemienowicz ML, Kruger SJ, Goh NS, Dobson JE, Spelman TD, Fabiny RP.

J Med Imaging Radiat Oncol. 2015 Oct;59(5):555-63. doi: 10.1111/1754-9485.12314. Epub 2015 May 12.

PMID:
25963240
34.

Be honest and help me prepare for the future: What people with interstitial lung disease want from education in pulmonary rehabilitation.

Holland AE, Fiore JF Jr, Goh N, Symons K, Dowman L, Westall G, Hazard A, Glaspole I.

Chron Respir Dis. 2015 May;12(2):93-101. doi: 10.1177/1479972315571925. Epub 2015 Feb 16.

PMID:
25687210
35.

Observation of handover process in an intensive care unit (ICU): barriers and quality improvement strategy.

Kowitlawakul Y, Leong BS, Lua A, Aroos R, Wong JJ, Koh N, Goh N, See KC, Phua J, Mukhopadhyay A.

Int J Qual Health Care. 2015 Apr;27(2):99-104. doi: 10.1093/intqhc/mzv002. Epub 2015 Feb 2.

PMID:
25644706
36.

Differences in the handover process and perception between nurses and residents in a critical care setting.

Mukhopadhyay A, Leong BS, Lua A, Aroos R, Wong JJ, Koh N, Goh N, See KC, Phua J, Kowitlawakul Y.

J Clin Nurs. 2015 Mar;24(5-6):778-85. doi: 10.1111/jocn.12707. Epub 2014 Nov 25.

PMID:
25421502
37.

Australian Idiopathic Pulmonary Fibrosis Registry: vital lessons from a national prospective collaborative project.

Moodley Y, Goh N, Glaspole I, Macansh S, Walters EH, Chapman S, Hopkins P, Reynolds PN, Zappala C, Cooper W, Mahar A, Ellis S, McCormack S, Darbishire W, Wood-Baker R, Corte TJ; Australian IPF Registry Steering Committee.

Respirology. 2014 Oct;19(7):1088-91. doi: 10.1111/resp.12358. Epub 2014 Aug 14.

38.

Dyspnoea and comorbidity contribute to anxiety and depression in interstitial lung disease.

Holland AE, Fiore JF Jr, Bell EC, Goh N, Westall G, Symons K, Dowman L, Glaspole I.

Respirology. 2014 Nov;19(8):1215-21. doi: 10.1111/resp.12360. Epub 2014 Aug 12.

39.

Prevalence and prognosis of unclassifiable interstitial lung disease.

Troy L, Glaspole I, Goh N, Zappala C, Hopkins P, Wilsher M, Moodley Y, Corte T.

Eur Respir J. 2014 May;43(5):1529-30. doi: 10.1183/09031936.00003414. No abstract available.

40.

Impaired chronotropic response to 6-min walk test and reduced survival in interstitial lung disease.

Holland AE, Hill CJ, Glaspole I, Goh N, Dowman L, McDonald CF.

Respir Med. 2013 Jul;107(7):1066-72. doi: 10.1016/j.rmed.2013.04.002. Epub 2013 May 10.

41.

Serum interleukin 6 is predictive of early functional decline and mortality in interstitial lung disease associated with systemic sclerosis.

De Lauretis A, Sestini P, Pantelidis P, Hoyles R, Hansell DM, Goh NS, Zappala CJ, Visca D, Maher TM, Denton CP, Ong VH, Abraham DJ, Kelleher P, Hector L, Wells AU, Renzoni EA.

J Rheumatol. 2013 Apr;40(4):435-46. doi: 10.3899/jrheum.120725. Epub 2013 Feb 1.

PMID:
23378460
42.

The benefits of exercise training in interstitial lung disease: protocol for a multicentre randomised controlled trial.

Dowman L, McDonald CF, Hill C, Lee A, Barker K, Boote C, Glaspole I, Goh N, Southcott A, Burge A, Ndongo R, Martin A, Holland AE.

BMC Pulm Med. 2013 Feb 1;13:8. doi: 10.1186/1471-2466-13-8.

43.

Idiopathic pulmonary fibrosis: is all-cause mortality a practical and realistic end-point for clinical trials?

Corte TJ, Goh NS, Glaspole IN, Zappala CJ, Hopkins PM, Wilsher ML.

Thorax. 2013 May;68(5):491-2. doi: 10.1136/thoraxjnl-2012-203114. Epub 2013 Jan 23. No abstract available.

PMID:
23345573
44.

Extent of disease on high-resolution computed tomography lung is a predictor of decline and mortality in systemic sclerosis-related interstitial lung disease.

Moore OA, Goh N, Corte T, Rouse H, Hennessy O, Thakkar V, Byron J, Sahhar J, Roddy J, Gabbay E, Youssef P, Nash P, Zochling J, Proudman SM, Stevens W, Nikpour M.

Rheumatology (Oxford). 2013 Jan;52(1):155-60. doi: 10.1093/rheumatology/kes289. Epub 2012 Oct 13.

PMID:
23065360
45.

The six-minute walk test in scleroderma: what should we measure and how should we measure it?

Holland AE, Goh NS.

Respirology. 2012 May;17(4):588-9. doi: 10.1111/j.1440-1843.2012.02161.x. No abstract available.

PMID:
22394399
46.

Predictors of benefit following pulmonary rehabilitation for interstitial lung disease.

Holland AE, Hill CJ, Glaspole I, Goh N, McDonald CF.

Respir Med. 2012 Mar;106(3):429-35. doi: 10.1016/j.rmed.2011.11.014. Epub 2011 Dec 17.

47.

Increased epithelial permeability in pulmonary fibrosis in relation to disease progression.

Goh NS, Desai SR, Anagnostopoulos C, Hansell DM, Hoyles RK, Sato H, Denton CP, Black CM, du Bois RM, Wells AU.

Eur Respir J. 2011 Jul;38(1):184-90. doi: 10.1183/09031936.00010910. Epub 2010 Oct 28.

48.

Differentiating between IPF and NSIP.

Glaspole I, Goh NS.

Chron Respir Dis. 2010 Aug;7(3):187-95. doi: 10.1177/1479972310376205. Review.

PMID:
20688895
49.

Anterior ischemic optic neuropathy associated with Vogt-Koyanagi-Harada disease.

Nakao K, Mizushima Y, Abematsu N, Goh N, Sakamoto T.

Graefes Arch Clin Exp Ophthalmol. 2009 Oct;247(10):1417-25. doi: 10.1007/s00417-009-1125-3. Epub 2009 Jun 30.

PMID:
19568763
50.

A new ent-kauranoid from Isodon lophanthoides var. geradianus.

Liu YH, Huang SX, Zhao QS, Ding JK, Goh NK, Sun HD, Chia TF, Tan SN, Chia LS.

Nat Prod Res. 2008;22(10):860-4. doi: 10.1080/14786410701640619.

PMID:
18626820

Supplemental Content

Support Center